No Data
No Data
Changjiang Pharmaceutical Group Co., Ltd.'s (SZSE:300391) 129% Share Price Surge Not Quite Adding Up
Changjiang Pharmaceutical Group Co., Ltd. (SZSE:300391) shareholders would be excited to see that the share price has had a great month, posting a 129% gain and recovering from prior weakness.
Changjiang Securities: Xtep Int'l's Q2 2024 revenue performance meets expectations, maintains a "buy" rating.
According to a research report released by Changjiang Securities, Xtep International (01368) maintains a 'buy' rating. Taking into account that KP has not yet been divested, it is estimated that the net profit attributable to the parent company will be 1.17 billion, 1.33 billion, and 1.48 billion yuan in 2024-2026, with a year-on-year growth of 14%, 13%, and 12% respectively. The company released retail data for 2024Q2, showing that Xtep's main brand revenue increased by about 10% year-on-year, with a 25% discount, a stock-to-sales ratio of about 4 months, and the revenue performance was in line with expectations. Looking ahead, the company's inventory and discounts will return to a healthy level, and there is still room for optimizing the gross margin and A&P expense ratio of the main brand of professional sports brands to continue.
Estimating The Fair Value Of Changjiang Publishing & Media Co.,Ltd (SHSE:600757)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Changjiang Publishing & MediaLtd fair value estimate is CN¥8.97 Changjiang Publishing & MediaLtd's CN¥8.21 share price indicates it is tradin
Changjiang Runfa Health Industry Gets Delisting Warning
Changjiang Runfa Health Industry (SHE:002435) received advanced notice of listing termination from the Shenzhen Stock Exchange, according to a Thursday filing with the bourse. The bourse cited the com
Changjiang & Jinggong Steel Building (Group) (SHSE:600496) Could Be A Buy For Its Upcoming Dividend
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Changjiang & Jinggong Steel Building (Group) Co., Ltd (SHSE:600496) is about to trade ex-divid
Changjiang Securities: First rating Miniso as 'buy', combining both future internal and external growth potential.
Changjiang Securities released a research report stating that it has initiated coverage of Miniso (09896) with a 'buy' rating and is expected to achieve a net income attributable to the parent company of RMB 2.84 billion, RMB 3.56 billion, and RMB 4.4 billion respectively for the latest fiscal year (calendar year) from 2024 to 2026. The bank believes that the company's future growth points are: 1) Endogenous: the company gradually shifts from cost-effective to high-gross-margin interest consumption, locks in 'big beauty', 'big toys', and 'big IP' to create a super category, and continues to explore the superstore strategy; 2) Exogenous: High-quality supply chain overseas expansion logic is expected to deepen continuously, and overseas store expansion has gone through years of supply chain and operation
No Data